Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Phenotypic Detection of Carbapenemase and AmpC‐β‐Lactamase Production among Extended Spectrum β‐Lactamase (ESBL)‐Producing Escherichia coli and Klebsiella spp., Isolated from Clinical Specimens

Zakaria Garba
* ,
Berenger Kaboré
,
Isidore Bonkoungou
,
Magloire H. Natama
,
ROUMBA Toussaint
ORCID logo ,
Kaisa Haukka
,
Juha P. Kirveskari
,
Halidou Tinto
,
Lassana Sangaré
,
Nicolas Barro
,
Anu Kantele
ORCID logo
Version 1 : Received: 9 November 2023 / Approved: 10 November 2023 / Online: 10 November 2023 (14:42:40 CET)

A peer-reviewed article of this Preprint also exists.

Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; Kantele, A. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics 2024, 13, 31. Garba, Z.; Kaboré, B.; Bonkoungou, I.J.O.; Natama, M.H.; Rouamba, T.; Haukka, K.; Kirveskari, J.P.; Tinto, H.; Sangaré, L.; Barro, N.; Kantele, A. Phenotypic Detection of Carbapenemase and AmpC-β-Lactamase Production among Extended Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella spp. Isolated from Clinical Specimens. Antibiotics 2024, 13, 31.

Abstract

Background In many African countries, clinical samples are not routinely tested for carbapenem-resistant bacteria, the resistance data remaining limited. Material and methods In March 2020 –June 2022, we collected extended spectrum β-lactamase (ESBL) -producing Enterobacterales (ESBL-PE) isolates from five hospitals in Burkina Faso. The species were identified using API20E and ESBL production confirmed by double-disc synergy test. Production of carbapenemases and AmpC-β-lactamases and phenotypic co-resistance were determined. Results Among the 473 ESBL-PE, 356 were ESBL- E. coli (ESBL-Ec) and 117 Klebsiella spp. (ESBL-K). Of the isolates, 5.3% were carbapenemase and 5.3% AmpC-β-lactamase positive Three types of carbapenemases were identified: 19 NDM, 3 OXA-48 like and 1 VIM. Two isolates produced both NDM and OXA48-like carbapenemases. Carbapenemase rates were highest among isolates in tertiary hospitals. Co-resistance rates were up to 85% for aminoglycosides, 90% for sulfonamides, 95% for fluoroquinolones and 25% for chloramphenicol, Fosfomycin resistance was 6% for ESBL-Ec and 49% for ESBL-K (49%). Conclusion Many ESBL-Ec and ESBL-K co-produced carbapenemases and/or AmpC-β-lactamases, at all healthcare levels and in various samples, with high co-resistance rates to non-betalactams. Carbapenem resistance is no longer rare, calling for testing in routine diagnostics, vigorous resistance surveillance system, and infection control within healthcare.

Keywords

ESBL; carbapenemase; AmpC‐β‐lactamase; E. coli; Klebsiella spp; hospitals

Subject

Public Health and Healthcare, Other

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.